Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
David J Mazzo is President & CEO at Lisata Therapeutics. OQRO lists 6 transactions filed with the SEC under this name, the latest on Jan 13, 2026, each linked to the official Form 4.
President & CEO
Disclosures on record
6
Companies involved
1
Lisata TherapeuticsLSTA
6 disclosures · Jan 2026
Jan 9, 202681Kdisclosed Jan 13
DetailsOfficial recordJan 9, 202640Kdisclosed Jan 13
DetailsOfficial recordJan 9, 202611Kdisclosed Jan 13
DetailsOfficial recordJan 9, 202611Kdisclosed Jan 13
DetailsOfficial recordJan 9, 202612Kdisclosed Jan 13
DetailsOfficial recordJan 9, 20267,854disclosed Jan 13
DetailsOfficial recordDavid J Mazzo bought shares on the open market in 2015, and has not bought since 2015.
David J Mazzo reported 1 open-market purchase and 0 sales since 2015; purchases in 2015.
| Year | Bought | Sold |
|---|---|---|
| 2015 | $28K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
David J Mazzo reported 1 open-market purchase and 0 sales here, 2015.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Jan 9, 2026, David J Mazzo reported holding 311,890 shares of Lisata Therapeutics (LSTA). At the last close of $1 on Nov 13, 2026, that is about $377K. This is the stake disclosed in filings, not a net worth.
Lisata Therapeutics's proxy statement reports total compensation of $1.15M for David J Mazzo for fiscal year 2025, after $1.69M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
David J Mazzo bought shares on the open market in 2015, and has not bought since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2015; no open-market sale is on record.
Lisata Therapeutics (LSTA), from 2015 to 2015: 1 purchase and 0 sales.
As of the latest filing on , David J Mazzo reported holding 311,890 shares of Lisata Therapeutics (LSTA), worth about $377K at the last close of $1 (Nov 13, 2026).
Lisata Therapeutics's proxy statement reports total compensation of $1.15M for David J Mazzo for fiscal year 2025, after $1.69M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Oct 19, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Lisata Therapeutics LSTA | 311,890 | 312K direct | $1 | $377K | Jan 9, 2026 |
Is this David J Mazzo’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
